PAVmed Inc. (PAVM)
NASDAQ: PAVM · Real-Time Price · USD
1.030
+0.010 (0.98%)
Nov 20, 2024, 4:00 PM EST - Market closed

Company Description

PAVmed Inc. focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States.

The company’s lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck.

Its product pipeline also comprises EsoCure EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform.

The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.

PAVmed Inc.
PAVmed logo
Country United States
Founded 2014
IPO Date Apr 28, 2016
Industry Medical Devices
Sector Healthcare
Employees 107
CEO Lishan Aklog

Contact Details

Address:
360 Madison Avenue, 25th Floor
New York, New York 10017
United States
Phone 917-813-1828
Website pavmed.com

Stock Details

Ticker Symbol PAVM
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001624326
CUSIP Number 70387R106
ISIN Number US70387R4039
Employer ID 47-1214177
SIC Code 3841

Key Executives

Name Position
Dr. Lishan Aklog M.D. Chairman and Chief Executive Officer
Dennis M. McGrath CPA President and Chief Financial Officer
Shaun M. O'Neill M.B.A. Executive Vice President and Chief Operating Officer
Michael Adam Gordon Executive Vice President, General Counsel and Secretary
Dr. Brian J. deGuzman M.D. Executive Vice President, Chief Technology and Compliance Officer
Dr. Suman M. Verma M.D., Ph.D. Senior Vice President of Molecular Genetics and Chief Scientific Officer
Michael Parks Vice President of Investor Relations
Dr. Deepika A. Lakhani Ph.D. Senior Vice President, Chief Regulatory and Quality Officer
Dr. Victoria T. Lee M.D. Senior Vice President and Chief Medical Officer

Latest SEC Filings

Date Type Title
Nov 14, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 8-K Current Report
Nov 14, 2024 10-Q Quarterly Report
Sep 23, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Sep 16, 2024 8-K Current Report
Aug 13, 2024 8-K Current Report
Aug 12, 2024 10-Q Quarterly Report
Jun 20, 2024 8-K Current Report
May 14, 2024 8-K Current Report
May 13, 2024 10-Q Quarterly Report